Oncotarget

Research Papers:

Is there a prognostic value of tumor location among Chinese patients with colorectal cancer?

Fangqi Liu, Cong Li, Huixun Jia, Li Yang, Yuchen Wu, Jiang Zhao, Sanjun Cai, Ji Zhu and Ye Xu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:38682-38692. https://doi.org/10.18632/oncotarget.16305

Metrics: PDF 1460 views  |   HTML 1228 views  |   ?  


Abstract

Fangqi Liu1,*, Cong Li1,*, Huixun Jia2,*, Li Yang1, Yuchen Wu1, Jiang Zhao1, Sanjun Cai1, Ji Zhu3 and Ye Xu1

1Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

2Department of Clinical Statistics, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

3Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

*These authors contributed equally to this work and should be regarded as joint first authors

Correspondence to:

Ye Xu, email: xuye021@163.com

Ji Zhu, email: leo.zhu@126.com

Keywords: colorectal cancer, tumor location, prognosis, left-sided colon cancer, right-sided colon cancer

Received: September 20, 2016     Accepted: February 21, 2017     Published: March 17, 2017

ABSTRACT

Differences in epidemiology, pathological features, and molecular pathogeneses have been observed according to primary tumor location in colorectal cancer (CRC). However, predicting CRC survival by tumor location remains controversial. Therefore, we compared the pathological characteristics, molecular features, and prognoses of right-side colon cancer (RCC), left-side colon cancer (LCC), and rectal cancer (RECC) among Chinese patients with CRC. We evaluated 4,426 patients with stage I–III CRC between January 2008 and July 2014from Fudan University Shanghai Cancer Center. All patients were grouped by the locations of tumors (RCC, LCC, and RECC). Patients with RCC were more likely to be women and older, have poorly differentiated tumors, microsatellite repair deficiency (dMMR), negative p53 expression, and the mucinous subtype. Unadjusted Kaplan-Meier survival curves revealed survival in RCC than in LCC and RECC. However, there were no significant differences in OS and DFS between LCC and RECC. The same results were observed for each disease stage. Unadjusted models revealed an increased risk of mortality, recurrence, or metastasis for RCC (OS: HR, 1.68, P=0.0002 and DFS: HR, 1.24, P=0.032), compared to LCC (all stages), and a similar result was observed for stage III patients (OS: HR, 1.79, P<0.0001 and DFS: HR, 1.33, P=0.021). However, adjusted Cox proportional hazard regression models revealed no significant differences in survival between the three tumor locations. Tumor location was not an independent prognostic factor among Chinese patients with stage I-III CRC. But RCCs had a worse prognosis in the dMMR subgroup. The related mechanism remains to be investigated.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16305